Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use GAMMAGARD S/D safely and effectively. See full prescribing information for GAMMAGARD S/D GAMMAGARD® S/D, Immune Globulin Intravenous (Human)IgA less than 1 microgram per mL in a 5% SolutionInitial U.S. Approval: 1994
Medication labelWhy this: Advisory · dailymed-other
Primary Immunodeficiency (PI) GAMMAGARD S/D is indicated for the treatment of primary immunodeficiency (PI) associated with defects in humoral immunity, in adults and children two years and older. This includes, but is not limited to, congenital agammaglobulinemia, common variable immunodeficiency, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies.1,2,3 B-cell Chronic Lymphocytic Leukemia (CLL) GAMMAGARD S/D is indicated for prevention of bacterial infections in patients with hypogammaglobulinemia and/or recurrent bacterial infections associated with B-cell chronic lymphocytic leukemia (CLL).4 Idiopathic Thrombocytopenic Purpura (ITP) GAMMAGARD S/D is indicated for the treatment of adult chronic idiopathic thrombocytopenic purpura to increase platelet count and to prevent and/or to control bleeding. Kawasaki Syndrome GAMMAGARD S/D is indicated for the prevention of coronary artery aneurysms associated with Kawasaki syndrome in pediatric patients.5
- generic_name
- immune globulin intravenous (human)
- brand_name
- water
- product_names
- Immune Globulin Intravenous (Human), water
- ndc
- 0944-2656, 0944-2656-03, 0944-2657, 0944-2657-07, 0338-0001, 0338-0001-77, 64764-512, 64764-512-96, 0944-2658, 0944-2658-04, 0944-2659, 0944-2659-08, 0338-0001-37, 64764-511, 64764-511-92
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en